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Abstract. 
 
We previously used subtractive hybridization 
to isolate cDNAs for genes upregulated in chick hyper-
trophic chondrocytes (Nurminskaya, M., and T.F. Lin-
 
senmayer. 1996. 
 
Dev. Dyn.
 
 206:260–271). Certain of 
these showed homology with the “A” subunit of human 
plasma transglutaminase (factor XIIIA), a member of a 
family of enzymes that cross-link a variety of intracellu-
lar and matrix molecules. We now have isolated a full-
length cDNA for this molecule, and confirmed that it is 
avian factor XIIIA. Northern and enzymatic analyses 
confirm that the molecule is upregulated in hyper-
trophic chondrocytes (as much as eightfold). The enzy-
matic analyses also show that appreciable transglutami-
nase activity in the hypertrophic zone becomes 
externalized into the extracellular matrix. This exter-
nalization most likely is effected by cell death and sub-
sequent lysis—effected by the transglutaminase itself. 
When hypertrophic chondrocytes are transfected with a 
cDNA construct encoding the zymogen of factor
XIIIA, the cells convert the translated protein to a 
lower molecular weight form, and they initiate cell 
death, become permeable to macromolecules and even-
tually undergo lysis. Non-hypertrophic cells transfected 
with the same construct do not show these degenerative 
changes. These results suggest that hypertrophic chon-
drocytes have a novel, tissue-specific cascade of mecha-
nisms that upregulate the synthesis of plasma trans-
glutaminase and activate its zymogen. This produces 
autocatalytic cell death, externalization of the enzyme, 
and presumably cross-linking of components within the 
hypertrophic matrix. These changes may in turn regu-
late the removal and/or calcification of this hyper-
trophic matrix, which are its ultimate fates.
Key words: transglutaminase • factor XIIIA • hy-
pertrophic chondrocyte • cell death • cartilage
 
D
 
URING
 
 the development of long bones, chondro-
cytes within the epiphyseal growth region un-
dergo proliferation, maturation, and hypertrophy.
During this progression, many cellular and matrix compo-
nents undergo developmentally regulated changes. For the
chondrocytes themselves these changes result in hypertro-
phy, and eventually apoptosis (Gibson et al., 1995, 1997)
or their transformation into osteogenic cells (Galotto et
al., 1994). The matrix undergoes calcification and/or re-
moval, and is ultimately replaced by bone or a marrow
cavity.
As chondrocytes enter the “hypertrophic program” they
undergo changes in their biosynthetic repertoire that
range from alterations in the collagens and proteoglycans
(Shinomura et al., 1984; Shinomura and Kimata, 1992) and
growth factors (Ballock et al., 1993), to the stimulation of
enzymes that degrade the matrix (Dean et al., 1985) or in-
duce calcification within it (Osdoby and Caplan, 1981;
Schmid et al., 1990; Kirsch and von der Mark, 1991). Re-
cently, another type of enzyme has been shown to be up-
regulated during hypertrophy—the molecular cross-linker,
transglutaminase (Aeschlimann et al., 1993, 1995; Nurmin-
skaya and Linsenmayer, 1996), which presumably alters
preexisting cellular and matrix components.
The transglutaminases comprise a family of Ca
 
2
 
1
 
-depen-
dent enzymes that catalyze the formation of 
 
g
 
-glutamyl
cross-links. Their substrates include a variety of macromo-
lecular components, both intracellular and extracellular,
so they can alter multiple properties of tissues in which
they are active. The family (Greenberg et al., 1991; Fesus
et al., 1996) consists of at least five members, including the
plasma form (also called coagulation factor XIII) and the
tissue/cytosolic form. Both of these forms have been
shown to be upregulated in hypertrophic cartilage—the
plasma form by subtractive hybridization as an upregu-
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lated gene in chick hypertrophic chondrocytes (Nurmin-
skaya and Linsenmayer, 1996), and the tissue form by im-
munohistochemical identification in hypertrophic cartilage
in rats (Aeschlimann et al., 1993) and in articular cartilage
in rabbits (Demignot et al., 1995).
The plasma transglutaminase molecule, as isolated from
blood, is a tetrameric zymogen (factor XIII) consisting of
two catalytic “A” subunits (termed factor XIIIA) and two
non-catalytic “B” subunits. Upon thrombin cleavage
within the A subunit, the complex dissociates, resulting in
the active enzyme composed only of A subunits. In certain
cell types, such as platelets and macrophages, factor XIII
can exist intracellularly as a dimer of two zymogenic A
subunits. The activation mechanism for this intracellular
form of factor XIII is unknown, but has been suggested to
involve conformational changes induced by the ionic envi-
ronment rather than proteolysis (Fesus et al., 1996). We
will show that hypertrophic chondrocytes most likely have
an intracellular mechanism for activation that involves
proteolytic cleavage of the zymogen.
Tissue transglutaminase differs, because it is monomeric
and cytosolic. It is expressed in certain cells, such as hepa-
tocytes and erythrocytes, and is upregulated in many cell
types undergoing apoptosis. For activation, its only known
requirement is a critical concentration of calcium (Fesus et
al., 1996).
Functions have been proposed for some transglutami-
nases. These include the plasma transglutaminase-medi-
ated stabilization of the fibrin matrix during blood clotting
and the keratinocyte transglutaminase cross-linking of the
keratin envelopes formed during epidermal cell differenti-
ation (Thacher, 1989). Tissue transglutaminase has been
implicated in many roles, including: the determination of
cell shape by cross-linking the actin cytoskeleton and its
associated proteins (Nemes et al., 1997), the promotion of
cell adhesion (Borge et al., 1996; Ueki et al., 1996), and the
stabilization of extracellular matrices (Aeschlimann et al.,
1995). Its activity has also been reported to correlate with
the regulation of cell growth and differentiation (Borge et
al., 1996; Katoh et al., 1996) and apoptosis (Borge et al.,
1996; Cummings, 1996; Fesus et al., 1996). As we will
show, the plasma transglutaminase that consists only of A
subunits (factor XIIIA) can also produce cell death—at
least in hypertrophic chondrocytes.
All the transglutaminases seem to be capable of cross-
linking a broad, similar range of substrates. Intracellular
substrates include proteins of the actin cytoskeleton (Zhu
et al., 1994) and histones (Ballestar et al., 1996); extracel-
lular substrates include certain collagens, osteopontin, vi-
tronectin and osteonectin (Mosher and Proctor, 1980;
Prince et al., 1991; Beninati et al., 1994; Aeschlimann et
al., 1996). Many of these are found in the hypertrophic car-
tilage matrix, and possibly, the extent to which these and
other components are cross-linked alters the susceptibility
of the matrix to proteolysis, and thus affects the rate of its
removal during development. Fibronectin, for example, is
sensitive to cleavage by MMPs only after it has been cross-
linked by transglutaminase (Bini et al., 1996).
The expression of two transglutaminases in hyper-
trophic chondrocytes—the tissue form that is constitu-
tively active, and the plasma form that requires proteolytic
activation—suggests that each may serve different roles.
 
In the present study, we have begun to elucidate these
functions in the avian growth cartilage, with emphasis on
the enzymatically activated form of factor XIIIA. We have
observed by sequencing and enzymatic assays, that factor
XIIIA is the major form of the molecule in avian growth
region cartilage, and that it is upregulated as much as
eightfold as the chondrocytes undergo hypertrophy. Since
neither factor XIIIA nor the tissue form of transglutami-
nase has a signal peptide, we examined the mechanism of
externalization. By transfection analyses, it seems likely
that externalization is effected through cell death and sub-
sequent lysis. When hypertrophic chondrocytes are trans-
fected with a cDNA construct encoding the zymogen of
factor XIIIA, the cells effect conversion of the translated
protein to a lower molecular weight form, and this occurs
concomitant with cell death. Subsequently the cells un-
dergo permeabilization/lysis, allowing for externalization
of the enzyme, and presumably of other cytoplasmic com-
ponents. Non-hypertrophic cells transfected with the same
construct show none of these changes. These results sug-
gest that hypertrophic chondrocytes have tissue-specific
mechanisms that upregulate the synthesis of plasma trans-
glutaminase and activate its zymogen, resulting in autocat-
alytic cell death and externalization of the enzyme.
 
Materials and Methods
 
Chondrocyte Culture
 
Cartilages were dissected from 14- or 20-d-old chicken embryos (Spafas
Inc., Norwich, CT). Hypertrophic chondrocytes were from the hyper-
trophic zone three (Kim and Conrad, 1977; Stocum et al., 1979; Schmid
and Conrad, 1982
 
a
 
) of the tibia. Non-hypertrophic chondrocytes were
from the caudal one-third of the sternum. Cells were dissociated by
0.125% trypsin (GIBCO BRL, Gaithersburg, MD), 0.3% collagenase type
I (Sigma Chemical Co., St. Louis, MO), and 0.6% bovine testes hyal-
uronidase type I (Sigma Chemical Co.), and then cultured in DME
(GIBCO BRL) containing 10% BCS (Hyclone Labs, Logan, UT) and 50
U/ml penicillin and streptomycin (GIBCO BRL). The hypertrophic chon-
drocytes were cultured for 2–4 wk and passaged three to four times before
use. We (Schmid and Conrad, 1982
 
b
 
; Schmid and Linsenmayer, 1983) pre-
viously observed that when chondrocytes from the hypertrophic zone are
put in cell culture, over a several-week period the relative synthesis of
type X collagen, a marker for mature hypertrophic chondrocytes, progres-
sively increases until it constitutes 
 
.
 
90% of the collagens being synthe-
sized. Thus, using such passaged cells ensures that the cells are mature,
hypertrophic chondrocytes. On the other hand, non-hypertrophic chon-
drocytes were cultured for only 3–4 d before use, since with extended time
in culture, some of these can progress to the hypertrophic state (Schmid
and Linsenmayer, 1983).
In some experiments, ascorbic acid (50 
 
m
 
g/ml) was added to the culture
medium, which was changed every other day.
 
Protein Extraction from Cartilage and Cell Cultures
 
Isolated pieces of sternum or hypertrophic cartilage were extracted in ice-
cold 50 mM Tris-HCl, pH 7.5, containing 0.15 M NaCl and protease inhib-
itors (2 mM DTT, 0.4 mM PMSF, 5 
 
m
 
g/ml leupeptin) for 2–4 h at 4
 
8
 
C. Af-
ter removal of this supernatant, termed “matrix extract,” the tissue was
homogenized in a lysis buffer to produce a “tissue extract.” Lysis buffer
consisted of 5 mM Tris-HCl, pH 7.5, 0.25 M sucrose, 0.2 mM Mg
 
2
 
SO
 
4
 
,
0.4% Triton X-100, and the same protease inhibitors as in the extraction
buffer. The total protein content was determined by the BCA Protein As-
say Reagent (Pierce Chemical Co., Rockford, IL).
For extracts of cell cultures, plates were rinsed twice with PBS, scraped
in PBS, and then centrifuged at 400 
 
g
 
 for 5 min. The cell pellets were
stored frozen at 
 
2
 
20
 
8
 
C until use. The cell pellets were suspended in the
same lysis buffer used for tissue homogenization, sonicated four times for 
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15 s at 10-s intervals, and then centrifuged at 13,000 
 
g
 
 for 5 min at 4
 
8
 
C. The
supernatant was collected and assayed for transglutaminase activity and
total protein.
 
Transglutaminase Assay
 
Transglutaminase activity was determined using a [
 
14
 
C]putrescine assay
described by Demignot et al. (1995), except that the reaction was stopped
by adding an equal volume of 10% TCA. TCA precipitates were collected
on Glass Microfibre filters (Whatman Inc., Clifton, NJ), washed three
times with 1 ml of ice-cold 5% TCA followed by 1 ml of 96% ethanol,
dried, and then counted in 10 ml of scintillation fluid (Beckman Ready
Safe). Enzyme activity was expressed as fmol of putrescine incorporated
per mg of protein in 1 min.
 
Preparation of RNA and Northern Analysis
 
PolyA
 
1
 
 RNA was isolated using a Fast Track Kit (Invitrogen Corp.,
Carlsbad, CA) and cDNA was synthesized using the cDNA Synthesis Sys-
tem (Amersham Corp., Arlington Heights, IL). Total RNA was isolated
with Trizol reagent (GIBCO BRL). RNA samples (2 
 
m
 
g polyA
 
1
 
 or 20 
 
m
 
g
total RNA) were subjected to electrophoresis through 1% agarose/2.2 M
formaldehyde gels and transferred to a HybondN filter (Amersham
Corp.). The filters were baked under vacuum and hybridized to labeled
probes as described in Sambrook et al. (1989). The probe for chicken
plasma transglutaminase was prepared by RT-PCR of hypertrophic chon-
drocyte cDNA using the following oligonucleotide primers: ATGTCT-
GAACCAGCGAGCAC (positions 94–114 in the partial cDNA sequence
[Nurminskaya and Linsenmayer, 1996]) and TAGGGTCGGCTGAA-
GTCTATCTG (reverse sequence for positions 327–350). Amplification
was performed for 30 cycles, with each cycle being at 94
 
8
 
C for 1 min, 56
 
8
 
C
for 1 min, and 72
 
8
 
C for 1.5 min.
 
5
 
9
 
- and 3
 
9
 
-RACE
 
To extend the lengths of the previously published (Nurminskaya and Lin-
senmayer, 1996) partial cDNA sequence for plasma transglutaminase, 5
 
9
 
-
and 3
 
9
 
-RACE was used, using a Marathon cDNA Amplification kit
(CLONTECH Laboratories, Inc., Palo Alto, CA). The primer used for
the 5
 
9
 
-RACE was TAGGGTCGGCTGAAGTCTATCTG (reverse se-
quence for positions 327–350) and for the 3
 
9
 
-RACE was GGCTCTG-
GAGACTGCTGTAATGT (positions 1,590–1,613 in the published se-
quence). The extended, amplified products were cloned into the plasmid
pCRII (TA cloning kit; Invitrogen). For each RACE product, 24–48 colo-
nies were picked and amplified by PCR using the same insert-specific
primers. The positive clones were then analyzed for insert size by PCR
amplification with vector primers.
 
DNA Sequencing
 
A set of gamma-delta transposon insertions (Strathmann et al., 1991) was
obtained for each clone to be sequenced that was longer than 0.6 kb. Each
clone was sequenced from both strands with at least threefold redun-
dancy. Sequencing was performed using a DyePrimer Cycle Sequencing
kit and the 373A automated DNA sequencer (PE Applied Biosystems,
Foster City, CA). The results were analyzed with the Sequencher software
program (GeneCodes Corp., Ann Arbor, MI).
 
Vector Construction, Transfection, and 
Immunochemical Analyses
 
A plasma factor XIIIA (FXIIIA)-green fluorescent protein (GFP)
 
1
 
 ex-
pression vector (pFXIIIA-GFP) was constructed using the pGreenLan-
tern-1 (GIBCO BRL) and pCR3.1 unidirectional expression vector (Invit-
rogen). A cDNA fragment encoding amino acid residues 1–555 of factor
XIIIA was obtained by RT-PCR of the hypertrophic chondrocyte cDNA
and cloned into pCR 3.1 following the manufacturer’s instructions.
pGreenLantern-1 vector was digested with NotI to obtain the DNA frag-
ment coding for GFP. This fragment was ligated into the NotI site of the
FXIIIA-pCR 3.1 plasmid. Transfections were performed in two-chamber
slides (for immunohistochemistry) or in 60-mm dishes (for Western blot
analysis). 7 
 
3 
 
10
 
4
 
 hypertrophic chondrocytes or 7 
 
3 
 
10
 
3
 
 non-hypertrophic
chondrocytes were transfected with 1 
 
m
 
g of DNA using 7 
 
m
 
l of lipofectin
(GIBCO BRL) according to the manufacturer’s instructions. At intervals
after transfection, the transfected cultures were analyzed by immunofluo-
rescence and immunoblotting. For immunofluorescence, the cells were
fixed in 4% PFA for 25 min at 4
 
8
 
C, permeabilized by methanol, and then
reacted with an anti–type X collagen mAb (Schmid and Linsenmayer,
1985). The nuclei were visualized by Hoechst staining. For immunoblot-
ting, the transfected cell cultures were washed with PBS and scraped into
Laemmli lysis buffer (150 
 
m
 
l/60-mm dish; with DTT). 20-
 
m
 
l aliquots were
analyzed on 4–20% gradient SDS-polyacrylamide gels (BIO-RAD Labo-
ratories, Hercules, CA). The proteins were transferred to nitrocellulose
membranes (BIO-RAD Laboratories), and the fusion proteins were de-
tected by reaction with an anti-GFP polyclonal antibody (CLONTECH
Laboratories, Inc.) followed by fluorescence visualization using an ECL
kit (Amersham Corp.).
 
In Situ Hybridization
 
Tibiotarsi were dissected from 14- and 20-d-old chicken embryos (Spafas
Inc., Norwich, CT) and fixed for 3 h in 4% PFA. Tissues were then washed
in PBS, dehydrated in a series of ethanols and xylene, and then embedded
in paraffin wax. Tissues were cut into 6-
 
m
 
m sections and mounted on Vec-
tabond-coated slides (Vector Laboratories, Burlingame, CA).
For in situ hybridization sections were dewaxed in xylene and rehy-
drated in a series of ethanol washes. After a 20-min wash in 0.2 N HCl in
PBS and two 5-min washes in PBS, the tissues were treated with 1 
 
m
 
g/ml
proteinase K for 30 min at 37
 
8
 
C, quenched with 0.1% glycine, refixed in
4% PFA for 10 min at RT, washed in PBS for 5 min and 0.1 M triethanol-
amine, pH 8.0, for 10 min, acetylated with 0.25% acetic anhydride for 10
min, and then dehydrated in a series of ethanol washes. Sections were
then air-dried for at least 1 h. The DIG-labeled riboprobes were diluted in
hybridization buffer (50% formamide, 10% dextran sulfate, 4
 
3 
 
SSC, 1
 
3
 
Denhardt’s solution, 1 mg/ml yeast tRNA, 10 mM DTT) to a final concen-
tration of 5 ng/
 
m
 
l for plasma transglutaminase. The probes were dena-
tured at 65
 
8
 
C for 10 min and hybridization was performed overnight in a
humid chamber at 52
 
8
 
C. To reduce non-specific background, the slides
were washed in 4
 
3 
 
SSC, incubated with 8.25 
 
m
 
g/ml RNase A for 30 min at
37
 
8
 
C, and finally washed in a series of SSC washes with decreasing salt
concentrations and increasing temperature. Slides were then incubated
overnight at RT with an alkaline phosphatase conjugated anti-digoxigenin
antibody (Boehringer Mannheim Corp., Indianapolis, IN), and the hy-
bridization signal was visualized by addition of NBT/BCIP.
 
Preparation of Riboprobes
 
Probes were amplified from cDNA, and the PCR fragments were ligated
into the pCR2.1 vector (Invitrogen). Plasmids containing the inserts in the
forward or reverse orientation were linearized with BamHI, and labeled
sense (negative control) or antisense RNA was generated by in vitro tran-
scription in the presence of digoxigenin-UTP and unlabeled nucleotides
using the T7 promoter. The 548-bp PCR fragment for the plasma trans-
glutaminase was generated with the forward primer CACCGACAGAG-
AGAAGAAACGACCTC and reverse primer TCAGTTGCCGAGTTT.
 
Results
 
Isolation and Characterization of a Full-Length cDNA 
for Plasma Transglutaminase (Factor XIIIA)
 
We previously used subtractive hybridization to isolate
cDNA clones for genes upregulated in chicken hyper-
trophic chondrocytes. Two of these clones, when extended
by RACE, generated products totaling 1.6 kb. The se-
quences of these showed high homology with the A sub-
unit of human plasma transglutaminase (factor XIIIA).
These clones were used as probes for Northern analyses
of total RNA from cell cultures of hypertrophic and non-
hypertrophic chondrocytes. The data (Fig. 1) give the size
of the mRNA as 4.3 kb.
To obtain a full-length cDNA we further used 5
 
9
 
- and
3
 
9
 
-RACE. This sequence shows an open reading frame of
2.5 kb, encoding a 749–amino acid protein with a predicted
 
1. 
 
Abbreviation used in this paper
 
: GFP, green fluorescent protein. 
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molecular mass of 
 
z
 
75 kD. The actual protein could, how-
ever, be somewhat larger, as two potential sites for 
 
N
 
-gly-
cosylation (N-Y-S sequence) are present (positions 345
and 549). The conceptual protein lacks a signal peptide, as
based on the hydrophobicity profile and the criteria of the
“-3,-1” rule (von Heijne, 1986). The deduced amino acid
sequence has 75% identity to human factor XIIIA (67%
identity at the nucleotide level). The identity is even
higher (up to 90%) within the functional domains respon-
sible for enzymatic activity (residues 319–347) and for
Ca
 
2
 
1
 
 binding (residues 468–488).
 
Upregulation of Plasma Transglutaminase mRNA in 
Hypertrophic Chondrocytes
 
To determine the course of the upregulation of plasma
transglutaminase during chondrocyte development we
first performed Northern analysis on hypertrophic and
non-hypertrophic chondrocytes cultured from two differ-
ent stages of embryos—14 d, which is a time when rapid
embryonic growth is still occurring, and 20 d, when growth
has reached a plateau in preparation for hatching. The
mRNA for the plasma transglutaminase (Fig. 1), when
normalized to that for the “housekeeping” enzyme
GAPDH, showed a relative increase in the hypertrophic
chondrocytes versus non-hypertrophic chondrocytes of
three- to fourfold in the cultures from 14-d embryos, and
six- to eightfold in those from 20-d embryos.
The upregulation was confirmed for growth cartilages in
vivo by in situ hybridization (Fig. 2). In the growth region
of tibiotarsi from 14-d embryos, the signal for plasma
transglutaminase shows a large increase in cells of the hy-
pertrophic zone (Fig. 2 
 
A
 
, and panels demarcated by 
 
ar-
rows
 
). In comparison to collagen type X protein, as visual-
ized by immunofluorescence (Fig. 2 
 
A
 
9
 
), the increased
signal for the transglutaminase seems to occur slightly ear-
lier than the appearance of this hypertrophic-specific col-
lagen.
 
2
 
 Both remain present throughout the remainder of
the hypertrophic zone. In tissues from 20-d embryos (Fig.
2 
 
B
 
), the mRNA for plasma transglutaminase becomes re-
stricted to a narrower zone. By comparison with the im-
munolocalization of the type X collagen (Fig. 2 
 
B
 
9
 
) this is
the zone of early hypertrophy.
 
Transglutaminase Activity
 
To determine whether transglutaminase enzymatic activ-
ity also becomes elevated during hypertrophy, we used the
standard assay measuring [
 
14
 
C]putrescine incorporation
into casein (Demignot et al., 1995). This was examined
both in cell cultures (Fig. 3) and in isolated tissues (Fig. 4;
Table I). Each sample was analyzed before and after
thrombin activation. The activity requiring thrombin should
reflect only the factor XIIIA, as this is the member of the
transglutaminase family that is synthesized as a zymogen.
The activity already present before thrombin treatment
(constitutive activity), however, is probably more com-
plex. In the non-hypertrophic cells, the constitutive activ-
ity should reflect largely the tissue form, as these cells do
not seem able to activate the factor XIIIA zymogen (see
below). In the hypertrophic cells, however, the constitutive
activity most likely includes both the tissue form and that
portion of the factor XIIIA that has already undergone ac-
tivation—since hypertrophic chondrocytes have the ability
to activate the zymogen intracellularly (shown later).
 
2. We used this combination of in situ hybridization and immunofluores-
cence to compare precisely the localizations of transglutaminase and type
X collagen in the same section. Obviously the immunofluorescence for the
type X collagen is visualizing the protein and not the mRNA. However,
we feel that this comparison is valid, since our previous studies on type X
collagen show concomitant appearance of the mRNA and protein.
Figure 1. Northern analysis of
factor XIIIA expression in hy-
pertrophic (Hyp) and non-
hypertrophic (NH) chondro-
cytes. Total RNA (10 mg) was
isolated from cell cultures
from 14- and 20-d-old em-
bryos. Relative abundance is
normalized to the housekeep-
ing gene GAPDH.
Figure 2. Upregulation of plasma transglutaminase in hyper-
trophic cartilage in vivo. In situ hybridization for factor XIIIA in
the tibiotarsal growth region of 14-d (A) or 20-d (B) embryos.
The arrows in A demarcate enlarged images from the pre-hyper-
trophic (top) and hypertrophic (bottom) zones. A9 and B9 are flu-
orescent images of the same field as in A and B reacted with a
mAb against collagen type X. 
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In lysates of hypertrophic and non-hypertrophic chon-
drocytes cultured from 14- or 20-d-old embryos (Fig. 3),
the constitutive activity (
 
solid bars
 
) was relatively low and
constant in both cell types. The major activity required
thrombin activation (Fig. 3, 
 
cross-hatched bars
 
), with this
being four- to sixfold greater in hypertrophic cells. These
observed differences in thrombin-activation between the
hypertrophic and non-hypertrophic cells are consistent
with those obtained for the mRNA of the plasma form,
 
which showed a similar degree of upregulation (above).
The culture media showed little of either type of activity, if
any at all (data not shown). Identical results were obtained
in cultures supplemented with exogenous ascorbic acid for
4–5 d preceding the assay.
To determine whether the enzymatic analyses of cells in
culture reflected the conditions in vivo, we examined
transglutaminase activities in freshly dissected cartilages
from the growth region of limbs. As shown in the diagram
in Table I, non-hypertrophic cartilage was from the upper
one-third of the growth region, which included the prolif-
erative zone and part of the zone of maturation, and hy-
pertrophic cartilage was from the lower one-third of the
region. For comparisons and controls, we also examined
the caudal sternum and bone marrow. The caudal sternum
is essentially a permanent cartilage, and thus provides a
pure source of non-hypertrophic material. Bone marrow is
virtually impossible to remove from the vascular channels
in hypertrophic cartilage, and thus is a potential source of
contaminating cells. If the enzymatic activity in marrow
were either low or nonexistent, it would ensure that our
results were not influenced by contaminant cells. For each
tissue, two fractions were examined. An extracellular/ma-
trix–associated pool (termed matrix extract) was obtained
by extraction of the intact tissue with 0.15 M NaCl (Fig. 4
 
A
 
), and an intracellular pool (termed tissue lysate) was ob-
tained by subsequent homogenization of the remaining
material in the presence of detergent (Fig. 4 
 
B
 
).
The data for 14-d-old tissues is shown in
 
 
 
Table I.
 
 
 
The
matrix extracts of the non-hypertrophic, caudal sternal
control showed no detectable constitutive enzyme, and af-
ter thrombin activation only a small amount of additional
activity was detected (data not shown). In the matrix of
the growth region of the limb, the non-hypertrophic zone
showed a small amount of constitutive activity, and after
thrombin activation, somewhat more. In the hypertrophic
zone both activities were increased five- to sixfold. Bone
marrow had essentially no activity. The tissue lysates in all
cartilages and zones contained most of the activity. The
constitutive activity again was minor and constant
throughout all of the zones, with most of the activity re-
quiring thrombin activation. In the hypertrophic zone the
thrombin-activated form was threefold greater than in the
non-hypertrophic zone of the limb and sevenfold higher
Figure 3. Enzymatic assays for plasma transglutaminase in cul-
tures of hypertrophic (Hyp) and non-hypertrophic (NH) chon-
drocytes. Activities were measured without thrombin activation
(solid bar) and with activation (cross-hatched bar). Cell cultures
were initiated with chondrocytes from 14- and 20-d-old embryos.
Figure 4. Transglutaminase enzymatic activity in non-hyper-
trophic (NH) and hypertrophic (Hyp) cartilage tissues dissected
from 14- and 20-d embryonic tibiotarsal growth regions. Both
matrix extract (neutral salt extractable) (A) and tissue lysate (de-
tergent extracted) (B) pools were examined, and activities were
measured both without thrombin activation (solid bar) and with
activation (cross-hatched bar).
 
Table I. Distribution of Transglutaminase Activity in the 
Growth Plate of the 14-d-old Chicken Embryo
 
Activity is given in fmol of [
 
14
 
C]putrescine incorporated into casein by 1 mg of total
protein in 1 min. 
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than in the caudal sternum. The bone marrow, again, had
little activity.
When these data on the 14-d limb tissues were com-
pared with those from 20-d embryos
 
 
 
(Fig. 4), the most ob-
vious difference was the heightened activity in the extra-
cellular matrix of the hypertrophic zone at the later stage.
In the tissue lysates from this zone, by far the major activ-
ity required thrombin activation (Fig. 4, 
 
cross-hatched
bars), and in the matrix extracts this thrombin-activated
(plasma) form also predominated. In the matrix extracts
constitutive activity was also elevated. However, since hy-
pertrophic chondrocytes can activate the plasma form,
which is subsequently released into the matrix (described
next), a large portion of this activity is also likely to be the
plasma transglutaminase.
Thus, these data on enzymatic activities are consistent
with the plasma form being the major transglutaminase in
developing avian growth cartilage, with this activity be-
coming greatly upregulated during hypertrophy and with
increasing developmental age. They also suggest that in
the hypertrophic region a large amount of plasma trans-
glutaminase (and presumably also the tissue form) is re-
leased into the matrix.
Transglutaminase Externalization
As neither the plasma nor tissue form of transglutaminase
possesses a consensus signal peptide, the question arises
how they become externalized, and, in growth cartilage,
why this preferentially occurs in the hypertrophic region.
Two possibilities were examined. One is that these en-
zymes are components of the matrix vesicles that are pref-
erentially shed from hypertrophic chondrocytes; the other
is that the enzymes are released after cell death. We failed
to detect transglutaminase in matrix vesicles isolated from
hypertrophic cell cultures (data not shown), so we exam-
ined the possible role of cell death. Cell death is known to
occur in 8–10% of the cells throughout the growth plate,
and this rises to 30% of the cells that have entered the hy-
pertrophic program (Gibson et al., 1995; Aizawa et al.,
1997). Also, the tissue form of transglutaminase has been
reported to be involved in apoptosis in other cell types.
To address this we transfected hypertrophic chondro-
cytes with an expression plasmid (pFXIIIA-GFP) contain-
ing a construct for the zymogen form of factor XIIIA
fused with GFP as a tag to identify the transfected cells.
The construct consisted of the coding sequence for the
first 555 amino acids of the transglutaminase linked to that
encoding 238 residues of GFP, all driven by a CMV pro-
moter. The construct was designed such that the size of the
fusion protein produced would be similar to that of the na-
tive protein. This was achieved by replacing the sequence
encoding 194 amino acids from the COOH-terminal end
of transglutaminase with 238 amino acid residues of GFP.
The only potential alteration this might produce in en-
zyme function would be a lowered catalytic efficiency.
Studies on human factor XIIIA have shown that deletion
of 218 amino acid residues from the COOH terminus re-
sults in a fourfold reduction in activity (Lai et al., 1996).
We transfected hypertrophic chondrocytes with this
construct and then examined the effect on the cells by flu-
orescence microscopy. After several days, the transfected
cells showed a spectrum of changes indicative of cellular
death, including shrunken and fragmented nuclei (Fig. 5 B,
middle column). Eventually, all that remained of the trans-
fected cells were patches of GFP-containing cytoplasm
(Fig. 5 B, right column). Control hypertrophic cells trans-
fected with a plasmid expressing GFP only showed no cel-
lular changes, and several days after transfection were
found frequently in nests of two or four cells, suggesting
that they had continued to undergo division (data not
shown).
Further evidence for transglutaminase-mediated cell ly-
sis and the release of cytoplasmic components was ob-
tained by immunohistochemistry with an antibody against
the GFP tag (Fig. 5). Shortly after transfection (2 d) with
the pFXIIIA-GFP plasmid (when cell nuclei still appeared
normal), the cells required permeabilization for reactivity
Figure 5. Fluorescence micrographs of hypertrophic (A and B)
and non-hypertrophic chondrocytes (C and D) transfected with
the full-length (A–C) and truncated (constitutively active) (D)
pFXIIIA-GFP constructs. Transfected cells (arrows) were identi-
fied by the intrinsic fluorescence of the GFP fusion protein (left
column); nuclear morphology was visualized by Hoechst staining
(middle column), and the integrity of cell membranes was deter-
mined by intracellular reactivity of non-permeabilized cells with
rhodamine-conjugated anti-GFP antibody (right column). 2 d
after transfection of hypertrophic cells with the full-length
FXIIIA-GFP construct (A) no changes are seen in the nuclear
morphology compared with non-transfected cells. Also, the fu-
sion FXIIIA-GFP protein in these non-permeabilized cells is not
reactive with the anti-GFP antibody. By 4 d (B), the Hoechst
staining shows shrunken and fragmented nuclei in those cells
transfected with pFXIIIA-GFP, and now the anti-GFP antibody
can penetrate the non-permeabilized cells and shows reactivity.
Non-hypertrophic chondrocytes, transfected with the pFXIIIA-
GFP construct, still maintain a normal nuclear morphology 6 d
after transfection (C). However, the nuclei of non-hypertrophic
chondrocytes transfected with the truncated (constitutively ac-
tive) pFXIIIA-GFP (D) become shrunken and fragmented by
day 4.Nurminskaya et al. Plasma Transglutaminase in Hypertrophic Chondrocytes 1141
with the anti-GFP antibody, suggesting that their mem-
branes were intact (Fig. 5 A). Later (4–5 d) after transfec-
tion, however, when nuclei were undergoing degenerative
changes, reactivity with the antibody could be achieved
without permeabilization (Fig. 5 B). Thus, the cell mem-
branes had become leaky to large macromolecules, or pos-
sibly had been destroyed.
Non-hypertrophic cells, when transfected with the full-
length pFXIIIA-GFP construct, encoding the zymogenic
form of FXIIIA exhibited no such degenerative changes
(Fig. 5 C). The nuclei did not undergo morphologically de-
generative changes, and the GFP fusion protein remained
in discrete cytoplasmic granules/vacuoles, the identity of
which is unknown. Thus, non-hypertrophic chondrocytes
either differ in their susceptibility to transglutaminase ac-
tivity, or they lack the ability to convert the zymogen to an
active enzyme.
To determine whether the non-hypertrophic chondro-
cytes are susceptible to the action of transglutaminase, we
transfected these cells with a truncated ptFXIIIA-GFP fu-
sion construct from which the inhibitory domain of the zy-
mogen had been removed (by deleting 144 amino acid res-
idues from the NH2-terminal end of the molecule). Thus,
the enzyme produced by this construct should be constitu-
tively active. Control hypertrophic cells transfected with
this truncated construct showed that the enzyme produced
was active. Such transfected cells underwent nuclear
changes that were indistinguishable from those of the cells
transfected with the full-length construct. Likewise, when
non-hypertrophic cells were transfected with this trun-
cated construct, they also underwent similar degradative
changes (Fig. 5 D). Thus, the non-hypertrophic cells are
not refractory to the effects of the enzyme. Instead, the
most likely reason they were unaffected by transfection
with the full-length construct was an inability to activate
the zymogen.
Hypertrophic Chondrocyte-mediated Conversion of
the Zymogen
Extracellular activation of the zymogen of human plasma
transglutaminase—as occurs during blood clotting—involves
thrombin-mediated cleavage of the A subunit at an Arg-
Gly site at position 38 (Fig. 6 A, circle in human sequence).
The transfections of the avian hypertrophic chondrocytes
described above, however, raise the possibility that this
cell type can activate the zymogen intracellularly. In the
chicken plasma transglutaminase, the deduced amino acid
sequence contains two Arg-Gly residues (at positions 46
and 87; see Fig. 6 A, boxes) that, by comparison to the hu-
man and other species, are potential sites for activation.
To examine which, if either, of these sites can be cleaved
by hypertrophic chondrocytes, cells were transfected with
the pFXIIIA-GFP construct. Then, 24 and 150 h later, cell
lysates were prepared and the molecular weight(s) of the
fusion protein were determined by Western blotting with
an antibody against the GFP moiety (Fig. 6 B). At 24 h af-
ter transfection only a single band was detected. At 150 h,
however, an additional lower molecular weight band was
also present. The difference in the molecular weights be-
tween these two is 8 kD, which is consistent with a pro-
teolytic cleavage at residue 85 (Fig. 6 A, circle in chicken
sequence). Thus, hypertrophic chondrocytes contain an in-
tracellular thrombin-like activity that can cleave the zy-
mogen form of plasma transglutaminase.
Discussion
Previous immunohistochemical studies showed an in-
creased level of the tissue form of transglutaminase in the
hypertrophic zone of the growth plate of juvenile rats (Ae-
schlimann et al., 1993, 1995). In agreement with this, we
(unpublished observations) also have observed the
mRNA for this form of the enzyme to be upregulated in
the hypertrophic zone of the avian growth region. Com-
pared with the plasma form (see below), however, this
represents a small portion of overall transglutaminase ac-
tivity produced by hypertrophic chondrocytes.
The possibility that more than one transglutaminase
might be present in cartilage was suggested by enzymatic
analysis of cultured rabbit articular chondrocytes. These
showed two activities that differed in their temporal pat-
terns of expression and in their responses to retinoic acid
(Demignot et al., 1995). The minor activity was later iden-
tified immunohistochemically as the tissue form, but the
major one was characterized only as activated by trypsin.
Trypsin is known to substitute for thrombin in activating
the plasma form of the molecule, raising the possibility
that the major activity was coming from factor XIII. Con-
sistent with this identification, as an upregulated gene in
hypertrophic chondrocytes we previously isolated a form
of transglutaminase that we tentatively identified as the A
subunit of factor XIII (Nurminskaya and Linsenmayer,
1996).
The additional data presented here solidify this identifi-
cation. The full-length cDNA shows 75% identity with the
A-chain of human factor XIII, as compared with only 47%
with the tissue form (from chicken erythrocytes). It has
Figure 6. (A) Amino acid alignment of the chicken (ChPTG) and
human (HFXIII) plasma transglutaminase. Asterisks indicate po-
tential translation start sites in the chicken. Boxes mark the Arg-
Gly residues of the potential activating sites at positions 46–47
and 87–88. Different sites are used by the chicken and human as
designated by the circles. (B) Immunoblot of extracts of hyper-
trophic chondrocytes transfected with the pFXIIIA-GFP con-
struct and probed with an antibody against the GFP moiety (B).
At 24 h after transfection, only a single band was detected (of the
size predicted for the zymogen), whereas by 150 h another band
was also present, suggesting the conversion/activation of some of
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both enzymatic and Ca21-binding regulatory domains, and
these show even higher (z90%) identity with human fac-
tor XIIIA. Also, like the factor XIIIA from other species,
it is synthesized as a zymogen that can be enzymatically
activated in in vitro assays by thrombin. The transfection
studies show that this zymogen can also be activated
within hypertrophic chondrocytes, and this, apparently, is
also by an enzymatic activity. The identity of this putative
enzyme within hypertrophic chondrocytes is still un-
known. However, the sequence cleaved (Arg-Gly) may be
the same as used by thrombin. The peptide removed by
hypertrophic chondrocytes from the zymogen is consistent
with cleavage of an Arg-Gly site found 85 amino acids
from the NH2-terminal end of the molecule. In the human
zymogen during blood coagulation an identical sequence
is cleaved at position 38.
Our data suggest that, in chicken growth cartilage, fac-
tor XIIIA is quantitatively the predominant transglutami-
nase, and that it undergoes appreciable upregulation dur-
ing chondrocyte maturation/hypertrophy. This was observed
at the level of mRNA, by both Northern analysis and in
situ hybridization. It was also observed at the level of en-
zymatic activity. Throughout the growth region, the larg-
est proportion of the activity requires thrombin activation,
and in the hypertrophic region this is increased greatly.
Also, at 20 d, as compared with 14 d, a much greater pro-
portion of the enzymatic activity is found in the matrix
fraction, suggesting a more active externalization—possi-
bly resulting in increased cross-linking of matrix compo-
nents, and through this either altering the rate of their re-
moval or promoting calcification of the matrix.
The ultimate fate of the transglutaminases in hyper-
trophic cartilage is to be released into the matrix. There,
most of the transglutaminase-induced cross-links are in
the non-collagenous fraction of the extracellular matrix
(Bowness and Tarr, 1997), with osteonectin and fibrillin
being two known substrates (Aeschlimann et al., 1995;
Bowness and Tarr, 1997). Additional substrates are also
likely to exist, such as fibronectin (Beninati et al., 1994;
Komarek et al., 1996), which is present in developing hy-
pertrophic cartilage (Chen and Linsenmayer, 1993). Im-
munohistochemical analysis (Aeschlimann et al., 1995) us-
ing antibodies against the major cross-link produced by
the enzyme (the g-Glu-e-Lys dipeptide), shows a low level
of reactivity in the zone of maturation, and this activity is
intracellular. In the zone of hypertrophy there is increased
activity, and much of this is now within the extracellular
matrix. Our enzymatic analyses are consistent with trans-
glutaminase activity becoming externalized into the extra-
cellular matrix of the hypertrophic zone. In this location, a
portion of the enzyme is already active (especially in the
older embryos) and a portion requires thrombin activa-
tion. The active enzyme could be comprised of both the
tissue form and the factor XIIIA that had already been ac-
tivated; the inactive enzyme most likely represents only
the factor XIIIA zymogen that has been externalized.
Externalization of the transglutaminase(s) into the ma-
trix is unlikely to occur through the conventional exocy-
totic pathway, as neither form has a consensus signal pep-
tide. Externalization of other proteins that lack a signal
peptide has been suggested to occur through a loosely de-
fined “non-conventional pathway,” or possibly through
cell lysis. In hypertrophic chondrocytes, one such non-con-
ventional pathway is through the shedding of membrane-
bound matrix vesicles, which are thought to be involved in
calcification (Wuthier et al., 1985). This pathway has been
suggested for externalization of tissue transglutaminase by
hypertrophic chondrocytes (Aeschlimann et al., 1995). We
were unable, however, to detect transglutaminase activity
in matrix vesicles isolated from cultures of hypertrophic
chondrocytes, although our preparations did contain alka-
line phosphatase, a marker for these structures (unpub-
lished observations). Thus, if transglutaminase is a compo-
nent of matrix vesicles, it must be in extremely low
concentration.
Instead, our data from transfection studies are most con-
sistent with a mechanism in which some portion of the
plasma transglutaminase zymogen undergoes intracellular
activation within hypertrophic chondrocytes, resulting in
cell death, lysis, and subsequent externalization of the ac-
tive enzyme, as well as the zymogen itself. The pFXIIIA-
GFP zymogen construct employed in these studies con-
tained the functional regions required for regulation (the
activation peptide and Ca21-binding domains) and for
cross-linking (the catalytic domain) (Lai et al., 1996).
Transfections of hypertrophic chondrocytes with this
construct led to morphological signs of nuclear degenera-
tion and cell death. The nuclear changes, as observed by
staining with Hoechst dye or propidium iodide, include
shrinkage, fragmentation, and eventual loss. We have not,
however, observed typical apoptotic staining of the nuclei
by end labeling (TUNEL). Thus, the transglutaminase-
induced cell death may differ from apoptotic death, both
in nuclear changes and in the fate of cytoplasmic compo-
nents. In general, it is believed that during apoptosis cyto-
plasmic components are not externalized (Jacobson et al.,
1997), but apparently they are during the transglutami-
nase-induced cell death.
Externalization of cytoplasmic components is an impor-
tant feature of our model, as this is required for the subse-
quent transglutaminase-mediated modifications of matrix
components. Observations suggest that transglutaminase-
induced cell death can result in externalization. Shortly
after transfection, when the nuclei still appear normal, im-
munohistochemical visualization of the intracellular trans-
glutaminase fusion protein (via its GFP moiety) requires
permeabilization of the cells. Later however, when signs of
nuclear degeneration are apparent, permeabilization is no
longer required for visualization of intracellular trans-
glutaminase. Thus, the cell membranes have become
“leaky” to macromolecules at least as large as the antibod-
ies used for immunohistochemical detection. Eventually
all that remains of the transfected cells are patches of
GFP-positive cytoplasm/matrix on the surface of the cul-
ture dish.
The cellular death caused by the factor XIIIA-GFP fu-
sion protein most likely requires activation of the zymogen
through a mechanism that seems specific/selective for hy-
pertrophic chondrocytes. However, the details of this
mechanism are unknown. The zymogen of factor XIII has
been detected in a variety of cells (Adany, 1996). How-
ever, only stimulated platelets and macrophages have been
shown capable of its intracellular activation (Muszbek et
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tivation. In hypertrophic chondrocytes, however, our
transfection studies suggest proteolytic activation is in-
volved, as immunoblotting showed intracellular conver-
sion of some factor XIIIA fusion protein zymogen to a
lower molecular weight form. This conversion is consistent
with cleavage at an Arg-Gly site that can also be cleaved
by thrombin or trypsin. The identity of the intracellular
protease involved remains to be determined. However, it
too is most likely an upregulated/specific component of
the hypertrophic program (see below), and through its
ability to effect activation of the zymogen, it potentially
adds another level of regulation to the transglutaminase-
mediated effects.
Specificity of this activation for hypertrophic cells is evi-
denced by the observation that non-hypertrophic cells
transfected with the same construct showed no indications
of the nuclear changes seen in hypertrophic cells. Instead,
these cells retained a healthy appearance, although they
clearly contained large amounts of GFP-labeled protein
localized in discrete cytoplasmic regions/structures that do
not colocalize with markers for either Golgi or lysosomes
(data not presented), and whose identity, therefore, is un-
known. The non-hypertrophic chondrocytes were not sim-
ply refractory to the action of the enzyme. These cells,
when transfected with a truncated construct from which
the activation domain had been removed (which thus pro-
duced constitutively active enzyme) underwent the se-
quence of morphological changes indicative of cellular
death. Therefore the non-hypertrophic cells most likely
lack the activation mechanism for the zymogen, or it is at a
much lower level (see below). Alternatively, they may
have a mechanism for sequestering the zymogen in a sub-
cellular compartment in which it is protected from activa-
tion.
Our determinations of enzymatic activity in vivo are
also consistent with intracellular activation of the enzyme
by hypertrophic chondrocytes. Appreciable enzymatic ac-
tivity is present in the hypertrophic matrix, and this in-
creases with developmental stage. As both the constitu-
tively active enzyme and the zymogen are present in the
extracellular matrix, not all the enzyme is required for the
proposed cell lysis.
This raises the question whether a critical level of active
enzyme (or time of exposure) results in cell death with the
subsequent release of active enzyme plus the remaining
store of zymogen. It also raises the question why massive
death is not observed in cultures of hypertrophic cells, un-
less the quantity of enzyme is artificially increased by
transfection with a transglutaminase-expressing construct.
At present, no definitive answers to these questions are
available. However, a major difference between hyper-
trophic chondrocytes in vivo (where a high proportion of
them die) and in cell culture (where they do not die) is cel-
lular proliferation. In vivo, hypertrophic chondrocytes are
postmitotic, but in culture they rapidly proliferate. Possi-
bly, cell division dilutes the enzyme or restricts the time
available for it to alter cellular component(s).
Once the enzyme is externalized, the number of sub-
strates potentially available for cross-linking is large, in-
cluding: osteonectin and collagen type II (Aeschlimann et
al., 1995), fibronectin (Mosher and Proctor, 1980; Ko-
marek et al., 1996) and cartilage matrix protein and the
proteoglycan aggrecan (Hauser et al., 1996). Transgluta-
minases may also stabilize heterotypic collagen fibrils, and
may even be involved in the activation of latent growth
factors (Kojima et al., 1997). The current observation that
two different forms of transglutaminase are present in hy-
pertrophic cartilage, at least in the chicken, adds an addi-
tional level of regulation for modifying these matrix mole-
cules during endochondral bone development. As the
substrate specificity of the tissue and plasma forms of the
enzyme are thought to be similar (Komarek et al., 1996),
their respective roles may be quantitative rather than
qualitative. It remains to be tested whether the changes ef-
fected by either enzyme alter calcification and/or removal
of the hypertrophic matrix, which are its ultimate fates.
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